General description
A cell-permeable, reversible, and ATP-competitive inhibitor against multiple protein kinases, including, but not limited to, CaM kinase II (Ki = 1.8 nM), myosin light chain kinase (Ki = 20 nM), protein kinase A (Ki = 18 nM), protein kinase C (Ki = 25 nM), protein kinase G (Ki = 20 nM), NGF receptor gp140trk (IC50 = 3 nM), its transforming trk oncogenes, and the related neurotrophin receptors gp145trkB and gp145trkC. Reported to induce apoptosis and cell cycle arrest by decreasing Cdk1 and Cdc25c activity in T98G cells and inhibit Flt3 phosphorylation in Flt3/Itd-BaF3 cells (IC50<50 nM). Also available as a premade 1 mM (100 µg/214 µl) solution in DMSO (Cat. No. 420297).
Biochem/physiol Actions
Primary Target
CaM kinase II
Target Ki: 1.8 nM, 20 nM, 18 nM, 25 nM, 20 nM, 3 nM, against CaM kinase II, myosin light chain kinase, protein kinase A, protein kinase C, protein kinase G, NGF receptor gp140trk, respectively
Warning
Toxicity: Standard Handling (A)
Reconstitution
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Other Notes
Cools, J., et al. 2004. Cancer Res. 64, 6385.
Chin, L.S., et al. 1999. Cancer Invest. 17, 391.
Tapley, P., et al. 1992. Oncogene 7, 371.
Hashimoto, Y. 1991. Biochem. Biophys. Res. Commun. 181, 423.
Nakanishi, S. 1988. J. Biol. Chem. 263, 6215.
Kase, H., et al. 1987. Biochem. Biophys. Res. Commun. 142, 436.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
- UPC:
- 41106202
- Condition:
- New
- Weight:
- 1.00 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- 420298-100UG